Hajime Sakakita

Hajime Sakakita

Auto-generated profile, based on publicly available information

Hajime Sakakita

National Institute of Advanced Industrial Science and Technology

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in Archives of Biochemistry and Biophysics
Verified
Journal Article
Closed access
KMKenji Miyamoto
Kenji Miyamoto
SISanae Ikehara
Sanae Ikehara
HTHikaru Takei
Hikaru Takei
YAYoshihiro Akimoto
Yoshihiro Akimoto
HSHajime Sakakita
Hajime Sakakita
YIYuzuru Ikehara
Yuzuru Ikehara

19 April 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YIYoko Iizumi
Yoko Iizumi
MYMasako Yudasaka
Masako Yudasaka
JKJaeho Kim
Jaeho Kim
HSHajime Sakakita
Hajime Sakakita
TTTsukasa Takeuchi
Tsukasa Takeuchi
TOToshiya Okazaki
Toshiya Okazaki
Chemical modification of carbon nanotube surface can controllably modulate their optical properties. Here we report a simple and effective synthesis method of oxygen-doped single-walled carbon nanotubes (o-SWCNTs), in which a thin film of SWCNTs is just irradiated under the UV light for a few minutes in air. By using this method, the epoxide-type oxygen-adducts (ep-SWCNTs) were produced in addition to the ether-type oxygen-adducts (eth-SWCNTs). The Treated (6, 5) ep-SWCNTs show a red-shifted luminescence at ~1280 nm, which corresponds to the most transparent regions for bio-materials. Immunoassay, fluorescence vascular angiography and observation of the intestinal contractile activity of mice were demonstrated by using the produced o-SWCNTs as infrared fluorescent labels and imaging agents.

1 January 2013 in Journal of Photopolymer Science and Technology
Verified
Journal Article
Closed access
YIYuzuru Ikehara
Yuzuru Ikehara
HSHajime Sakakita
Hajime Sakakita
NSNobuyuki Shimizu
Nobuyuki Shimizu
SISanae Ikehara
Sanae Ikehara
HNHayao Nakanishi
Hayao Nakanishi

2 December 2015 in Plasma Processes and Polymers
Verified
Journal Article
Closed access
PDF file
SISanae Ikehara
Sanae Ikehara
HSHajime Sakakita
Hajime Sakakita
KIKenji Ishikawa
Kenji Ishikawa
YAYoshihiro Akimoto
Yoshihiro Akimoto
TYTakashi Yamaguchi
Takashi Yamaguchi
YIYuzuru Ikehara
Yuzuru Ikehara

13 December 2017 in Pathology International
Verified
Journal Article
Open access
PDF file
JIJun‐Ichiro Ikeda
Jun‐Ichiro Ikeda
HTHiromasa Tanaka
Hiromasa Tanaka
KIKenji Ishikawa
Kenji Ishikawa
HSHajime Sakakita
Hajime Sakakita
YIYuzuru Ikehara
Yuzuru Ikehara
MHMasaru Hori
Masaru Hori
Medical non‐thermal plasma (NTP) treatments for various types of cancers have been reported. Cells with tumorigenic potential (cancer‐initiating cells; CICs) are few in number in many types of tumors. CICs efficiently eliminate anti‐cancer chemicals and exhibit high‐level aldehyde dehydrogenase (ALDH) activity. We previously examined the effects of direct irradiation via NTP on cancer cells; even though we targeted CICs expressing high levels of ALDH, such treatment affected both non‐CICs and CICs. Recent studies have shown that plasma‐activated medium (PAM) (culture medium irradiated by NTP) selectively induces apoptotic death of cancer but not normal cells. Therefore, we explored the anti‐cancer effects of PAM on CICs among endometrioid carcinoma and gastric cancer cells. PAM reduced the viability of cells expressing both low and high levels of ALDH. Combined PAM/cisplatin appeared to kill cancer cells more efficiently than did PAM or cisplatin alone. In a mouse tumor xenograft model, PAM exerted an anti‐cancer effect on CICs. Thus, our results suggest that PAM effectively kills both non‐CICs and CICs, as does NTP. Therefore, PAM may be a useful new anti‐cancer therapy, targeting various cancer cells including CICs.

1 January 2017 in Journal of Clinical Biochemistry and Nutrition
Verified
Journal Article
Open access
KMKenji Miyamoto
Kenji Miyamoto
SISanae Ikehara
Sanae Ikehara
HSHajime Sakakita
Hajime Sakakita
YIYuzuru Ikehara
Yuzuru Ikehara
Low temperature plasma (LTP) coagulation equipment, which avoids causing burn injuries to patients, has been introducing into minimally invasive surgery. The mechanism by which this equipment stops bleeding is to directly occupy the injury with the formed blood clots, and different from the mechanism of the common electrical hemostatic devices that cauterize the tissues around the bleeding to stem the blood flow. A noteworthy point is that LTP treatment with our equipment is not confined only to the blood coagulation system, but it has significant effects on the other blood components to form clots with or without hemolysis, and that there is a plasma current threshold that determines whether the treatment makes stable clots. In this review, we introduce the clinical benefits of LTP current and describe the clot formation it facilitates.